Meningococcal B Vaccination Strategies and Their Practical Application in Italy

Overview

Journal J Prev Med Hyg

Specialty Public Health

Date 2016 Jan 21

PMID 26788734

Citations 7

Authors

R Gasparini

D Amicizia

P L Lai

D Panatto

Affiliations

Soon will be listed here.

Abstract

Immunisation against meningococcal meningitis has a long history, which has passed through several phases: the studies by Flexner, extraction of the polysaccharide capsule, the development of monovalent and multivalent conjugate vaccines, the outer membrane vesicle vaccines up to the development of effective and safe vaccines for meningococcal B invasive disease through the application of the techniques of molecular biology and reverse vaccinology. The new available vaccines are Bexsero® and Trumenba®. Bexsero ® has been approved and is available in Europe, the USA, Canada, Australia and Chile, and is currently under review in Brazil for the prevention of MenB invasive disease in subjects ≥ 2 months. Trumemba® is currently approved only in the USA, for use in adolescents and young adults. At present, the greatest obstacle to the extensive use of these vaccines in industrialised countries is the high cost and the need administer multiple doses in infants. However, in some European countries and in some Italian Regions, strategies (free and active call) to fight the disease through vaccination (Bexsero®) are already in place.

Citing Articles

Molecular characteristics of Neisseria meningitidis in Qatar.

Mahmoud Hamed M, Mir F, Elmagboul E, Al-Khal A, Rahman S Al Maslamani M, Deshmukh A Sci Rep. 2021; 11(1):4812.

PMID: 33637840 PMC: 7910605. DOI: 10.1038/s41598-021-84262-1.

Awareness, Attitudes, and Practices Toward Meningococcal B Vaccine among Pediatricians in Italy.

Ferrara P, Stromillo L, Albano L Medicina (Kaunas). 2018; 54(6).

PMID: 30513993 PMC: 6306744. DOI: 10.3390/medicina54060100.

Hospitalization rates and outcome of invasive bacterial vaccine-preventable diseases in Tuscany: a historical cohort study of the 2000-2016 period.

Chiappini E, Inturrisi F, Orlandini E, de Martino M, de Waure C BMC Infect Dis. 2018; 18(1):396.

PMID: 30103691 PMC: 6090664. DOI: 10.1186/s12879-018-3316-1.

Prevalence and serogroup changes of Neisseria meningitidis in South Korea, 2010-2016.

Lee H, Seo Y, Kim K, Lee K, Choe K Sci Rep. 2018; 8(1):5292.

PMID: 29593277 PMC: 5871844. DOI: 10.1038/s41598-018-23365-8.

Bioengineered polyester beads co-displaying protein and carbohydrate-based antigens induce protective immunity against bacterial infection.

Gonzalez-Miro M, Rodriguez-Noda L, Farinas-Medina M, Cedre-Marrero B, Madariaga-Zarza S, Zayas-Vignier C Sci Rep. 2018; 8(1):1888.

PMID: 29382864 PMC: 5789850. DOI: 10.1038/s41598-018-20205-7.

References

Christensen H, Hickman M, Edmunds W, Trotter C . Introducing vaccination against serogroup B meningococcal disease: an economic and mathematical modelling study of potential impact. Vaccine. 2013; 31(23):2638-46. PMC: 3743045. DOI: 10.1016/j.vaccine.2013.03.034. View

Fletcher L, Bernfield L, Barniak V, Farley J, Howell A, Knauf M . Vaccine potential of the Neisseria meningitidis 2086 lipoprotein. Infect Immun. 2004; 72(4):2088-100. PMC: 375149. DOI: 10.1128/IAI.72.4.2088-2100.2004. View

Gotschlich E, Liu T, Artenstein M . Human immunity to the meningococcus. 3. Preparation and immunochemical properties of the group A, group B, and group C meningococcal polysaccharides. J Exp Med. 1969; 129(6):1349-65. PMC: 2138651. DOI: 10.1084/jem.129.6.1349. View

Resti M, Micheli A, Moriondo M, Becciolini L, Cortimiglia M, Canessa C . Comparison of the effect of antibiotic treatment on the possibility of diagnosing invasive pneumococcal disease by culture or molecular methods: a prospective, observational study of children and adolescents with proven pneumococcal infection. Clin Ther. 2009; 31(6):1266-73. DOI: 10.1016/j.clinthera.2009.06.010. View

Guzzetta G, Manfredi P, Gasparini R, Panatto D, Edmunds W . On the relationship between meningococcal transmission dynamics and disease: remarks on humoral immunity. Vaccine. 2009; 27(25-26):3429-34. DOI: 10.1016/j.vaccine.2009.01.092. View

Leca M, Bornet C, Montana M, Curti C, Vanelle P . Meningococcal vaccines: Current state and future outlook. Pathol Biol (Paris). 2015; 63(3):144-51. DOI: 10.1016/j.patbio.2015.04.003. View

Goldschneider I, Gotschlich E, Artenstein M . Human immunity to the meningococcus. I. The role of humoral antibodies. J Exp Med. 1969; 129(6):1307-26. PMC: 2138650. DOI: 10.1084/jem.129.6.1307. View

Panatto D, Amicizia D, Lai P, Cristina M, Domnich A, Gasparini R . New versus old meningococcal group B vaccines: how the new ones may benefit infants & toddlers. Indian J Med Res. 2014; 138(6):835-46. PMC: 3978970. View

Stefanelli P, Fazio C, Neri A, Boros S, Renna G, Pompa M . Changing epidemiology of Infant Meningococcal Disease after the introduction of meningococcal serogroup C vaccine in Italy, 2006-2014. Vaccine. 2015; 33(31):3678-81. DOI: 10.1016/j.vaccine.2015.06.032. View

10.

Christensen H, May M, Bowen L, Hickman M, Trotter C . Meningococcal carriage by age: a systematic review and meta-analysis. Lancet Infect Dis. 2010; 10(12):853-61. DOI: 10.1016/S1473-3099(10)70251-6. View

11.

Murphy E, Andrew L, Lee K, Dilts D, Nunez L, Fink P . Sequence diversity of the factor H binding protein vaccine candidate in epidemiologically relevant strains of serogroup B Neisseria meningitidis. J Infect Dis. 2009; 200(3):379-89. DOI: 10.1086/600141. View

12.

Kaaijk P, van Straaten I, van de Waterbeemd B, Boot E, Levels L, van Dijken H . Preclinical safety and immunogenicity evaluation of a nonavalent PorA native outer membrane vesicle vaccine against serogroup B meningococcal disease. Vaccine. 2013; 31(7):1065-71. DOI: 10.1016/j.vaccine.2012.12.031. View

13.

Gotschlich E, Goldschneider I, Artenstein M . Human immunity to the meningococcus. IV. Immunogenicity of group A and group C meningococcal polysaccharides in human volunteers. J Exp Med. 1969; 129(6):1367-84. PMC: 2138657. DOI: 10.1084/jem.129.6.1367. View

14.

Trotter C, Gay N, Edmunds W . Dynamic models of meningococcal carriage, disease, and the impact of serogroup C conjugate vaccination. Am J Epidemiol. 2005; 162(1):89-100. DOI: 10.1093/aje/kwi160. View

15.

Martinon-Torres F, Gimenez-Sanchez F, Bernaola-Iturbe E, Diez-Domingo J, Jiang Q, Perez J . A randomized, phase 1/2 trial of the safety, tolerability, and immunogenicity of bivalent rLP2086 meningococcal B vaccine in healthy infants. Vaccine. 2014; 32(40):5206-11. DOI: 10.1016/j.vaccine.2014.07.049. View

16.

Mascioni A, Bentley B, Camarda R, Dilts D, Fink P, Gusarova V . Structural Basis for the Immunogenic Properties of the Meningococcal Vaccine Candidate LP2086. J Biol Chem. 2008; 284(13):8738-46. PMC: 2659232. DOI: 10.1074/jbc.M808831200. View

17.

Azzari C, Canessa C, Lippi F, Moriondo M, Indolfi G, Nieddu F . Distribution of invasive meningococcal B disease in Italian pediatric population: implications for vaccination timing. Vaccine. 2013; 32(10):1187-91. DOI: 10.1016/j.vaccine.2013.09.055. View

18.

Rappuoli R . Reverse vaccinology, a genome-based approach to vaccine development. Vaccine. 2001; 19(17-19):2688-91. DOI: 10.1016/s0264-410x(00)00554-5. View

19.

Trotter C, Borrow R, Andrews N, Miller E . Seroprevalence of meningococcal serogroup C bactericidal antibody in England and Wales in the pre-vaccination era. Vaccine. 2003; 21(11-12):1094-8. DOI: 10.1016/s0264-410x(02)00630-8. View

20.

Maiden M, Ibarz-Pavon A, Urwin R, Gray S, Andrews N, Clarke S . Impact of meningococcal serogroup C conjugate vaccines on carriage and herd immunity. J Infect Dis. 2008; 197(5):737-43. PMC: 6767871. DOI: 10.1086/527401. View